Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
IGC BIO
AddedFeb 17, 2024
UpdatedJun 18, 2026
IGC BIO

IGC BIO

Seed

IGC BIO: A Boston-based scientific platform for antibody creation, founded in 2014.

HQ
Boston, MA, US
Founded
2014
Overview
Compare
Fundraising
Employees

IGC BIO is a medical organization currently based in Boston, Massachusetts, United States.

It has been founded in 2014 by Dror Baran.

IGC BIO - Similar Companies

GRO Biosciences logo

GRO Biosciences

grobio.com

BioClonetics Immunotherapeutics logo

BioClonetics Immunotherapeutics

Abintus Bio logo

Abintus Bio

abintusbio.com

Illuminare Biotechnologies logo

Illuminare Biotechnologies

illuminarebio.com

IgGenix logo

IgGenix

iggenix.com

Abwiz Bio logo

Abwiz Bio

abwizbio.com

GentiBio logo

GentiBio

gentibio.com

Idbiologics logo

Idbiologics

idbiologics.com

Appia Bio logo

Appia Bio

appiabio.com

Upstream Bio logo

Upstream Bio

upstreambio.com

Hinge Bio logo

Hinge Bio

hingebio.com

Adimab logo

Adimab

adimab.com

AlaMab Therapeutics logo

AlaMab Therapeutics

alamab.com

Apriori Bio logo

Apriori Bio

aprioribio.com

Artax Biopharma logo

Artax Biopharma

artaxbiopharma.com

IGC BIO - Quick Facts

Who are IGC BIO's competitors?

Companies similar to IGC BIO include GRO Biosciences, BioClonetics Immunotherapeutics, Abintus Bio and Illuminare Biotechnologies.

When was IGC BIO founded?

IGC BIO was founded in 2014.

Where is IGC BIO's headquarters located?

IGC BIO's headquarters is located in Boston, MA, US.

When was IGC BIO's last funding round?

IGC BIO's most recent funding round was for $2.2M (USD) in July 2018.

How much has IGC BIO raised to-date?

As of Jul 24, 2018, IGC BIO has raised a total of $4.7M (USD).

How many employees does IGC BIO have?

IGC BIO has 5 employees as of Feb 5, 2024.

IGC BIO - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
Main Product
  • Antibodies
Tags
  • Platform
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified